Clinical trial
Safety and Efficacy Trial of Serostim® in the Treatment of Subjects With Human…
NCT00294164 · EMD Serono, Industry · Completed
Key facts
| NCT number | NCT00294164 |
|---|---|
| Title | Safety and Efficacy Trial of Serostim® in the Treatment of Subjects With Human Immunodeficiency Virus-associated Adipose Redistribution Syndrome (HARS) |
| Official title | Phase 2/3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group, Dose-finding, Safety and Efficacy Trial of Subcutaneously Administered Serostim® (Mammalian Cell-derived Recombinant Human Growth Hormone, r-hGH) in the Treatment of Human Immunodeficiency Virus-associated Adipose… |
| Lead sponsor | EMD Serono, Industry |
| Status | Completed |
| Phase | Phase 2/Phase 3 |
| Study type | Interventional |
| Conditions | Human Immunodeficiency Virus-associated Adipose Redistribution Syndrome (HARS), Human Immunodeficiency Virus Infections |
| Intervention type | Drug |
| Interventions | Serostim®, Placebo |
| Enrollment | 245 |
| Start date | Mar 1, 2001 |
| Primary completion | May 1, 2002 |
| Completion | May 1, 2002 |
| First posted | Feb 20, 2006 |
| Last update posted | Mar 26, 2014 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: